Viatris Inc.
VTRS
Hisse Senetlerindeki Sıralama
#1102
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its... Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.
Hisse Fiyatı
$18.50
Son senkronizasyon: 2026-10-20
Piyasa Değeri
$21.24B
Değişim (1 gün)
1.29%
Değişim (1 yıl)
78.01%
Ülke
US
Ticaret Viatris Inc. (VTRS)
Kategori
Healthcare
Viatris Inc. (VTRS) için gelir
Jun 2026 itibarıyla gelir TTM: $14.74B
Viatris Inc. şirketinin en son finansal raporlarına göre, mevcut geliri (TTM) $14.74B'dir. 2023 yılında şirketin geliri $15.43B önceki yıla göre azalma 2022 yılındaki $16.26B gelirine göre. Gelir, bir şirketin mal veya hizmet satışından elde ettiği toplam tutardır. Kazançtan farklı olarak, hiçbir gider düşülmez.
Viatris Inc. için 2004 ile 2026 arasındaki gelir geçmişi
Her yılın sonunda gelir
| Yıl | Gelir | Değiştir |
|---|---|---|
| 2026 (TTM) | $14.74B | -0.01% |
| 2024 | $14.74B | -4.46% |
| 2023 | $15.43B | -5.14% |
| 2022 | $16.26B | -9.08% |
| 2021 | $17.89B | 49.73% |
| 2020 | $11.95B | 3.87% |
| 2019 | $11.50B | 0.58% |
| 2018 | $11.43B | -3.98% |
| 2017 | $11.91B | 7.50% |
| 2016 | $11.08B | 17.47% |
| 2015 | $9.43B | 22.15% |
| 2014 | $7.72B | 11.73% |
| 2013 | $6.91B | 1.66% |
| 2012 | $6.80B | 10.87% |
| 2011 | $6.13B | 12.46% |
| 2010 | $5.45B | 7.02% |
| 2009 | $5.09B | -0.87% |
| 2008 | $5.14B | 76.85% |
| 2007 | $2.91B | 131.08% |
| 2006 | $1.26B | 0.30% |
| 2005 | $1.25B | -8.82% |
| 2004 | $1.37B | 0.00% |
Benzer şirketler veya rakiplerin geliri
| Şirket | Gelir | Gelir Farkı | Ülke |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | -55.14% |
IN
|
